Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;33(7):2219-2228.
doi: 10.1007/s11695-023-06633-z. Epub 2023 May 10.

Effect of Metabolic and Bariatric Surgery on the Clinical Course of Multiple Sclerosis in Patients with Severe Obesity: a Systematic Review

Masoumeh Shahsavan  1 , Bassem Amr  2 , Sonja Chiappetta  3 , Mohammad Kermansaravi  4   5
Affiliations

Effect of Metabolic and Bariatric Surgery on the Clinical Course of Multiple Sclerosis in Patients with Severe Obesity: a Systematic Review

Masoumeh Shahsavan et al. Obes Surg. 2023 Jul.

Abstract

Multiple sclerosis (MS) is an autoimmune inflammatory condition affecting the central nervous system (CNS). A systematic review following the PRISMA guidelines was performed to explore the effect of metabolic and bariatric surgery (MBS) on the clinical course and outcomes in patients with multiple sclerosis. Eleven articles examining 394 patients were included in the final analysis. The mean MS duration at the time of surgery was 7.6 ± 4.6 years, and the mean postoperative follow-up was 35.5 ± 5.3 months. MBS leads to the same weight loss with the same complication rate as in patients without MS. Most of patients experienced improvement in clinical course of MS after MBS, compared to non-surgical group. However, there is a risk for MS exacerbation in a number of patients after MBS; they should not be disadvantaged from having MBS, since surgery leads to the same weight loss outcomes with the same complication rate as in patients without MS.

Keywords: Bariatric surgery; Metabolic surgery; Multiple sclerosis; Obesity.

PubMed Disclaimer

References

    1. Papiri G, D'Andreamatteo G, Cacchiò G, Alia S, Silvestrini M, Paci C, et al. Multiple sclerosis: inflammatory and neuroglial aspects. Curr Issues Mol Biol. 2023;45(2):1443–70. https://doi.org/10.3390/cimb45020094 . - DOI - PubMed - PMC
    1. Vidal-Jordana A, Montalban X. Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects. Neuroimaging Clin N Am. 2017;27(2):195–204. - DOI - PubMed
    1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet (London, England). 2018;391(10130):1622–36. - DOI - PubMed
    1. Altieri C, Speranza B, Corbo MR, Sinigaglia M, Bevilacqua A. Gut-microbiota, and multiple sclerosis: background, evidence, and perspectives. Nutrients. 2023;15:4. - DOI
    1. Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023;33(1):3–14. - DOI - PubMed

Publication types

LinkOut - more resources